Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Earns “Buy” Rating from HC Wainwright

Armata Pharmaceuticals (NYSEAMERICAN:ARMP)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 270.37% from the company’s previous close.

Armata Pharmaceuticals Stock Performance

ARMP stock traded down $0.06 during midday trading on Thursday, hitting $1.89. The stock had a trading volume of 10,713 shares, compared to its average volume of 12,196. The stock has a market capitalization of $68.38 million, a P/E ratio of -1.15 and a beta of 0.78. Armata Pharmaceuticals has a 12-month low of $1.89 and a 12-month high of $4.48.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.